Macrogenics (MGNX) Assets Average (2013 - 2026)
Macrogenics' (MGNX) quarterly Assets Average came in at $237.4 million in Q1 2026, down 2.37% year-on-year from $243.1 million in Q1 2025, and down 10.02% on a QoQ basis from $263.8 million in Q4 2025.
Macrogenics (MGNX) Assets Average (2013 - 2026) Analysis & Trends
Macrogenics (MGNX) has 14 years of Assets Average data on file, last reported at $237.4 million in Q1 2026.
- On a quarterly basis, Assets Average fell 2.37% year-over-year to $237.4 million in Q1 2026; TTM through Mar 2026 was $237.4 million, a 2.37% decrease from a year earlier, with the FY2025 full-year figure at $259.3 million, down 7.42% from the prior year.
- Assets Average for Q1 2026 stood at $237.4 million, down from $263.8 million in the prior quarter.
- Over the last five years, Assets Average for MGNX reached as high as $324.6 million in Q2 2023 and fell as low as $206.7 million in Q3 2022.
- Historically, Assets Average has averaged $264.9 million across 5 years, with a median of $258.1 million in 2025.
- Across the five-year window, Assets Average plunged 49.47% in 2022 and jumped 56.18% in 2023, its largest moves.
- Year by year, Assets Average stood at $237.9 million in 2022, then surged by 34.17% to $319.2 million in 2023, then dropped by 17.58% to $263.1 million in 2024, then grew by 0.28% to $263.8 million in 2025, then declined by 10.02% to $237.4 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $237.4 million in Q1 2026, $263.8 million in Q4 2025, and $258.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Macrogenics | 254.43 Mn | 187.92 Mn | - | 237.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 237.36 Mn |
| Dec 31, 2025 | 263.80 Mn |
| Sep 30, 2025 | 258.09 Mn |
| Jun 30, 2025 | 234.99 Mn |
| Mar 31, 2025 | 243.11 Mn |
| Dec 31, 2024 | 263.07 Mn |
| Sep 30, 2024 | 232.81 Mn |
| Jun 30, 2024 | 224.71 Mn |
| Mar 31, 2024 | 273.35 Mn |
| Dec 31, 2023 | 319.20 Mn |
| Sep 30, 2023 | 322.81 Mn |
| Jun 30, 2023 | 324.58 Mn |
| Mar 31, 2023 | 311.98 Mn |
| Dec 31, 2022 | 237.91 Mn |
| Sep 30, 2022 | 206.70 Mn |
| Jun 30, 2022 | 244.74 Mn |
| Mar 31, 2022 | 303.35 Mn |
| Dec 31, 2021 | 363.70 Mn |
| Sep 30, 2021 | 409.04 Mn |
| Jun 30, 2021 | 430.68 Mn |